ArticleOncogene2026
The miR-302 family suppresses tumor growth in tongue squamous cell carcinoma by directly targeting P65.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tongue squamous cell carcinoma (TSCC) is an aggressive malignancy with a poor prognosis. The miR-302 family of microRNAs regulates stemness and differentiation, but its role in TSCC remains unknown. Here, we report that miR-372-3p, miR-302c-3p, and miR-520a-3p function as potent tumor suppressors in TSCC. These miRNAs inhibited cell proliferation, clonogenic growth, and induced apoptosis in vitro and in vivo. Transcriptomic analysis revealed that miR-302 overexpression silences pro-survival and inflammatory pathways. We found that these miRNAs directly target the NF-κB subunit P65 (RELA), which is upregulated in TSCC. Knockdown of P65 recapitulated the tumor-suppressive effects of miR-302, whereas P65 reconstitution partially rescued apoptosis and growth inhibition caused by miR-302. Both P65 knockdown and miR-302 overexpression dramatically slowed tumor growth in vivo. Our results demonstrate the therapeutic potential of a novel miR-302/P65 axis that limited the progression of TSCC by regulating apoptosis and oncogenic transcription.
Indexed as
Identifiers
42324384What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.